D&A at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s D&A?
- Immunovant, Inc. (IMVT) reported D&A of $96K in Q1 2026.
- How has Immunovant, Inc.'s D&A changed year-over-year?
- Immunovant, Inc.'s D&A decreased by 11.9% year-over-year, from $109K to $96K.
- What is the long-term trend for Immunovant, Inc.'s D&A?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s D&A has grown at a 34.2% compound annual growth rate (CAGR), from $126K to $409K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.